IMV (TSE:IMV) is scheduled to be posting its quarterly earnings results before the market opens on Friday, March 22nd. Analysts expect IMV to post earnings of C($0.09) per share for the quarter.
TSE IMV opened at C$5.44 on Friday. The firm has a market capitalization of $278.49 million and a P/E ratio of -12.11. IMV has a 12 month low of C$5.18 and a 12 month high of C$9.49. The company has a quick ratio of 4.57, a current ratio of 4.86 and a debt-to-equity ratio of 80.22.
A number of equities research analysts recently commented on the company. Echelon Wealth Partners reissued a “speculative buy” rating on shares of IMV in a research report on Thursday, December 13th. National Bank Financial lowered their price target on IMV from C$12.00 to C$11.00 and set an “outperform” rating for the company in a research report on Tuesday, March 5th.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2019/03/15/imv-imv-scheduled-to-post-earnings-on-friday.html.
IMV Company Profile
IMV Inc, a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.